Serina Therapeutics, a private biopharmaceutical company specializing in the design and development of patented polymer therapeutics, has entered into a definitive merger agreement with AgeX Therapeutics, a biotechnology company focused on developing therapeutics for human aging and regeneration. The combined company will operate under the Serina Therapeutics name.
Key Highlights
- The merger will combine Serina’s expertise in polymer therapeutics with AgeX’s focus on aging and regeneration therapeutics.
- The combined company will continue to advance its pipeline of polymer therapeutics and AgeX’s cell and drug-based therapeutic candidates for various diseases.
- Both CEOs emphasize the merger’s potential to provide additional resources and expand their therapeutic pipelines.
Source: Business Wire
Notable Quotes
- “This merger with AgeX provides Serina with a public platform to advance our polymer therapeutics platform and continue the development of our lead programs,” – Randall Moreadith, M.D., Ph.D., CEO of Serina Therapeutics.
- “The merger with Serina is expected to provide AgeX with additional resources to advance our current product candidates and expand our therapeutic pipeline,” – Michael D. West, Ph.D., CEO of AgeX Therapeutics
SoH's Take
- The merger between Serina Therapeutics and AgeX Therapeutics represents a strategic move to combine expertise in polymer therapeutics and aging therapeutics, potentially leading to innovative treatments for various diseases.
- With the combined resources and platforms, the merged entity is poised to accelerate the development of their respective pipelines, offering potential growth opportunities in the biopharmaceutical sector.
